June 27th 2024
Key opinion leaders are introduced and present a concise overview of the topics to be addressed.
January 10th 2024
Nicole Lamanna, MD, looks ahead at the future of treatment of B-cell malignancies, highlighting exciting therapeutic developments.
January 3rd 2024
A hematologist/oncologist discusses ongoing research on targeted therapy for patients with relapsed/refractory chronic lymphocytic leukemia.
Comprehensive insights on clinical and patient factors that inform treatment selection and sequencing for patients with B-cell malignancies.
December 27th 2023
Expert perspectives on the toxicities seen with targeted therapies in chronic lymphocytic leukemia and how they’re mitigated and managed.
An expert on hematologic malignancies discusses recent data from ASH 2023 in relapsed/refractory CLL/SLL, highlighting the ALPINE study investigating zanubrutinib versus ibrutinib.
December 21st 2023
Nicole Lamanna, MD, discusses the results from the ongoing BGB-11417-101 study investigating combination zanubrutinib plus sonrotoclax in patients with treatment-naïve CLL/SLL.
A hematologist/oncologist previews updated data presented at ASH 2023 for patients with B-cell malignancies.
Nicole Lamanna, MD, gives an overview of targeted therapies and the role of prognostic markers in the treatment of B-cell malignancies.
December 5th 2023
Expert insights into the evolving treatment landscape for chronic lymphocytic leukemia (CLL), emphasizing upcoming clinical data to be presented at ASH 2023.
December 1st 2023
Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.
March 8th 2023
Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.
An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.
March 1st 2023
Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.
Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.
February 22nd 2023
Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.
Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.
February 15th 2023
Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.
February 8th 2023
Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.